Skip to main content
Premium Trial:

Request an Annual Quote

Marina Inks Partnership for Bladder Cancer Program

Premium

Marina Biotech said this week that it has signed an exclusive deal to work with Swiss biopharmaceuticals group Debiopharm to develop and commercialize its preclinical bladder cancer program.

Under the terms of the deal, the companies will work together to advance the RNAi drug candidate, but Debiopharm will have “full responsibility for the development and commercialization of any products arising from the partnership.” Marina stands to receive up to $25 million based on “predefined research and development milestones,” as well as royalties on product sales, the firms said.

Additional terms were not disclosed.

Bladder cancer had been Marina's lead program, with the company anticipating a phase I study as early as 2012 (GSN 13/25/2010). However, when it acquired Cequent Pharmaceuticals last year, that company's investigational treatment for familial adenomatous polyposis, which is expected to enter the clinic this year, moved to the forefront (GSN 11/18/2010).

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.